Title
Safety and Efficacy of INGAP-Peptide in Patients With Type 2 Diabetes
A Randomized, Double-blind, Placebo-controlled, Rising-dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Insulin-using Type 2 Diabetes Mellitus Patients
Phase
Phase 2Lead Sponsor
Exsulin CorporationStudy Type
InterventionalStatus
Completed No Results PostedIndication/Condition
Diabetes Mellitus, Non-Insulin-DependentIntervention/Treatment
ingap peptide ...Study Participants
126Insulin is a chemical that the body needs in order to use or store sugar. It is made by a type of cell called a beta cell which resides in an organ known as the pancreas. Type 2 diabetes is a disease where the beta cells are unable to meet a person's insulin needs. Sugar levels rise in the blood as a result. INGAP-Peptide is being tested to attempt to create new beta cells in the pancreas, and to improve the ability to produce insulin in type 2 diabetic patients.
1.5 mL, once daily, self-administered SC injection for 90 days
1.5 mL, once daily, self-administered SC injection for 90 days
1.5 mL, once daily, self-administered SC injection for 90 days
Inclusion Criteria Age 35-70 Using >20 Units of insulin per day HbA1c from 6.5% to 10% No islet antibodies Otherwise healthy